Drug giant Gilead Sciences has waved green to provide drugs that decrease the hazard of HIV transmission for around 200,000 people per year, according to the Trump government.
The agreement between Gilead and the Trump government will last until at least December 31, 2025, or by the 2030 end, Health and Social Affairs Minister Alex Azar said in a statement on Thursday. Gilead will make a contribution of its drug PrEP medication Truvada, which is utilized to diminish the threat of HIV infection and is typically sold in the United States for $ 1600-2000 per month.
“The agreement will help us reach our objective of eradicating the HIV epidemic in America”, Said President Donald Trump in a tweet.
Trump is firm on a notion to end the HIV epidemic in the United States by 2030, which is a long-sought purpose of public health advocates. As per the latest data from the Joint United Nations Program on HIV/AIDS, about 36.9 Million people worldwide are living with HIV or AIDS and about 21.7 million people are using antiretroviral drugs to suppress HIV / AIDS infection.
Gilead has announced that it will provide its Truvada pill until Descovy, a second-generation version is made available. The Trump administration has decided to cover up the costs coupled with distributing drugs.
“Ensuring this commitment is a crucial step in the Trump government’s efforts to use the prevention and treatment tools we have to end the HIV epidemic in America by 2030,” he said. Gilead Sciences, headquartered in California, leads the annual $26 Billion HIV drug market.
Moreover, with several HIV treatments already in the work, recently developed drugs focus more on convenience. Drug makers are coming up with drugs that can be taken in the span of weeks.